CytoDyn Inc.
CYDY
$0.25
-$0.01-2.40%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.71% | 6.46% | -39.55% | -45.19% | -0.56% |
| Depreciation & Amortization | -- | -- | 44.00% | -28.57% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.60% | 94.07% | -23.64% | 17.25% | 9.09% |
| Operating Income | -37.60% | -94.07% | 23.64% | -17.25% | -9.09% |
| Income Before Tax | -374.14% | -128.81% | 64.52% | 60.08% | 50.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -374.14% | -128.81% | 64.52% | 60.08% | 50.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -374.14% | -128.81% | 64.52% | 60.08% | 50.14% |
| EBIT | -37.60% | -94.07% | 23.64% | -17.25% | -9.09% |
| EBITDA | -37.62% | -94.30% | 23.65% | -17.35% | -9.23% |
| EPS Basic | -333.33% | -128.31% | 69.82% | 66.40% | 59.62% |
| Normalized Basic EPS | -20.00% | -12.00% | 44.44% | 42.22% | 40.48% |
| EPS Diluted | -376.19% | -129.38% | 54.44% | 66.40% | 59.62% |
| Normalized Diluted EPS | -20.00% | -16.67% | 44.44% | 42.22% | 40.48% |
| Average Basic Shares Outstanding | 3.24% | 10.35% | 22.27% | 25.05% | 27.36% |
| Average Diluted Shares Outstanding | 3.24% | 4.53% | 22.27% | 25.05% | 27.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |